Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Boronic Acids | 3 | 2014 | 19 | 1.170 |
Why?
|
| Granulocytes | 2 | 2023 | 28 | 1.170 |
Why?
|
| Pyrazines | 3 | 2014 | 23 | 1.170 |
Why?
|
| Multiple Myeloma | 4 | 2014 | 32 | 1.020 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 209 | 0.920 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 756 | 0.790 |
Why?
|
| HIV Infections | 3 | 2023 | 2207 | 0.790 |
Why?
|
| Neutrophils | 2 | 2023 | 124 | 0.780 |
Why?
|
| Lung | 2 | 2019 | 413 | 0.680 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 79 | 0.650 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 211 | 0.620 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 2128 | 0.590 |
Why?
|
| Apoptosis | 4 | 2014 | 1317 | 0.550 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 19 | 0.490 |
Why?
|
| NF-kappa B | 2 | 2014 | 306 | 0.470 |
Why?
|
| Pyrimidines | 3 | 2010 | 112 | 0.450 |
Why?
|
| Interleukin-6 | 2 | 2013 | 140 | 0.430 |
Why?
|
| Doxorubicin | 2 | 2012 | 80 | 0.400 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 336 | 0.390 |
Why?
|
| Piperazines | 3 | 2010 | 109 | 0.390 |
Why?
|
| Caveolin 1 | 1 | 2010 | 27 | 0.390 |
Why?
|
| Blast Crisis | 1 | 2010 | 2 | 0.380 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 9 | 0.380 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 35 | 0.370 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 65 | 0.360 |
Why?
|
| RNA Interference | 1 | 2010 | 225 | 0.350 |
Why?
|
| Cohort Studies | 2 | 2022 | 1422 | 0.330 |
Why?
|
| Quinazolines | 1 | 2008 | 31 | 0.330 |
Why?
|
| Curcumin | 1 | 2008 | 66 | 0.320 |
Why?
|
| Humans | 15 | 2023 | 34853 | 0.290 |
Why?
|
| Mice | 6 | 2022 | 5668 | 0.280 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 22 | 0.210 |
Why?
|
| Histones | 1 | 2023 | 177 | 0.210 |
Why?
|
| Actins | 1 | 2022 | 142 | 0.210 |
Why?
|
| Fibrosis | 1 | 2022 | 146 | 0.210 |
Why?
|
| Fibroblasts | 2 | 2022 | 252 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 160 | 0.200 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 87 | 0.190 |
Why?
|
| Mice, SCID | 2 | 2010 | 143 | 0.190 |
Why?
|
| Phenotype | 1 | 2022 | 650 | 0.190 |
Why?
|
| Animals | 6 | 2022 | 14307 | 0.190 |
Why?
|
| Cell Lineage | 2 | 2019 | 88 | 0.180 |
Why?
|
| Proteomics | 1 | 2022 | 302 | 0.180 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2009 | 4 | 0.180 |
Why?
|
| Drug Synergism | 3 | 2008 | 171 | 0.180 |
Why?
|
| Signal Transduction | 4 | 2014 | 1802 | 0.180 |
Why?
|
| Mesoderm | 1 | 2019 | 70 | 0.170 |
Why?
|
| Aging | 1 | 2023 | 639 | 0.170 |
Why?
|
| Adipocytes | 1 | 2019 | 54 | 0.170 |
Why?
|
| Phosphorylation | 3 | 2013 | 878 | 0.170 |
Why?
|
| Gestational Age | 1 | 2019 | 190 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 109 | 0.160 |
Why?
|
| Inflammation | 1 | 2022 | 577 | 0.160 |
Why?
|
| Pregnancy | 2 | 2022 | 1503 | 0.160 |
Why?
|
| Deoxyribonuclease I | 1 | 2016 | 25 | 0.150 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 608 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 283 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 1530 | 0.140 |
Why?
|
| K562 Cells | 3 | 2010 | 31 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2019 | 562 | 0.140 |
Why?
|
| Benzamides | 3 | 2010 | 76 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2561 | 0.130 |
Why?
|
| Cells, Cultured | 1 | 2019 | 1442 | 0.130 |
Why?
|
| Cell Proliferation | 3 | 2009 | 1149 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 649 | 0.130 |
Why?
|
| Thalidomide | 1 | 2014 | 4 | 0.130 |
Why?
|
| Syndecan-1 | 1 | 2014 | 9 | 0.130 |
Why?
|
| Ubiquitination | 1 | 2014 | 54 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 41 | 0.120 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 31 | 0.120 |
Why?
|
| Cell Movement | 1 | 2016 | 545 | 0.110 |
Why?
|
| Female | 7 | 2022 | 19873 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2016 | 294 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 391 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2012 | 70 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 325 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 43 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 27 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 114 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 178 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 75 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2010 | 323 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2009 | 834 | 0.090 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2009 | 1 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2009 | 1 | 0.090 |
Why?
|
| Myelopoiesis | 1 | 2009 | 2 | 0.090 |
Why?
|
| Tandem Repeat Sequences | 1 | 2009 | 9 | 0.090 |
Why?
|
| Leukemia, Myeloid | 1 | 2009 | 8 | 0.090 |
Why?
|
| Transfection | 1 | 2010 | 496 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 29 | 0.090 |
Why?
|
| Interleukin-7 | 1 | 2008 | 7 | 0.090 |
Why?
|
| Cattle | 1 | 2010 | 472 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2008 | 45 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 781 | 0.080 |
Why?
|
| Luciferases | 1 | 2008 | 62 | 0.080 |
Why?
|
| Coculture Techniques | 1 | 2008 | 96 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 420 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2008 | 132 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 90 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2010 | 490 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 80 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 52 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 120 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 287 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 34 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 445 | 0.070 |
Why?
|
| Amides | 1 | 2007 | 66 | 0.070 |
Why?
|
| Monocytes | 1 | 2009 | 258 | 0.070 |
Why?
|
| Male | 4 | 2019 | 18870 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1300 | 0.070 |
Why?
|
| Cytokines | 1 | 2008 | 569 | 0.060 |
Why?
|
| Mutation | 1 | 2009 | 1023 | 0.060 |
Why?
|
| Middle Aged | 4 | 2013 | 9642 | 0.060 |
Why?
|
| Galectin 3 | 1 | 2023 | 26 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 137 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 111 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 165 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 114 | 0.040 |
Why?
|
| Prognosis | 2 | 2009 | 707 | 0.040 |
Why?
|
| Risk Factors | 1 | 2023 | 3414 | 0.030 |
Why?
|
| Aged | 3 | 2013 | 6448 | 0.030 |
Why?
|
| STAT Transcription Factors | 1 | 2013 | 10 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2013 | 34 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 20 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2013 | 19 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2013 | 40 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2012 | 28 | 0.030 |
Why?
|
| Cisplatin | 1 | 2012 | 70 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 88 | 0.030 |
Why?
|
| Adult | 3 | 2013 | 11034 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 260 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 480 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 12 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2009 | 9 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 43 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 67 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 80 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 298 | 0.020 |
Why?
|
| Adolescent | 2 | 2009 | 5035 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 431 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 310 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 605 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 383 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 166 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2007 | 32 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 580 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 2333 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 146 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 600 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2007 | 309 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 1152 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 220 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2009 | 1961 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 4012 | 0.010 |
Why?
|